Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the next steps and future development for vyxeos in AML, which include a better understanding of the drug and its impact on overall survival in other subsets of AML.
Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the next steps and future development for vyxeos in AML, which include a better understanding of the drug and its impact on overall survival in other subsets of AML.